bile duct cancer
FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx
Truseltiq is a new option for FGFR2 fusion-positive, locally advanced, or metastatic cholangiocarcinoma patients who have received prior treatment.
Innovent Biologics Begins Phase III Trial of First-Line Pemazyre for Bile Duct Cancer in China
The firm, which has rights to Incyte's agent in the country, is evaluating the drug versus chemo for cholangiocarcinoma patients harboring FGFR2 fusions.
QED Therapeutics, Helsinn Group Ink $2B Agreement to Codevelop Infigratinib in Oncology
The partners will both commercialize infigratinib in oncology in the US while Helsinn can develop it in certain markets for indications other than skeletal dysplasias.
European Commission Approves Incyte's Pemazyre for Rare Bile Duct Cancer
This will be the first treatment available in the EU for FGFR2 fusion-positive, advanced cholangiocarcinoma patients.
Incyte's Pemazyre Approved in Japan for Biliary Tract Cancer With FGFR2 Fusions
Japanese regulators approved the drug based on results of the FIGHT-202 trial showing that 36 percent of patients on pemigatinib responded to the treatment.